Search Results - "Johnstone, Megan E"

Grade-Dependent Metabolic Reprogramming in Kidney Cancer Revealed by Combined Proteomics and Metabolomics Analysis by Wettersten, Hiromi I, Hakimi, A Ari, Morin, Dexter, Bianchi, Cristina, Johnstone, Megan E, Donohoe, Dallas R, Trott, Josephine F, Aboud, Omran Abu, Stirdivant, Steven, Neri, Bruce, Wolfert, Robert, Stewart, Benjamin, Perego, Roberto, Hsieh, James J, Weiss, Robert H

“…Kidney cancer [or renal cell carcinoma (RCC)] is known as "the internist's tumor" because it has protean systemic manifestations, suggesting that it utilizes…”
Get full text

Inhibition of Enhancer of Zeste Homolog 2 Induces Blast Differentiation, Impairs Engraftment and Prolongs Survival in Murine Models of Acute Myeloid Leukemia by Fobare, Sydney, Elgamal, Ola A, Wunderlich, Mark, Stahl, Emily, Mehmood, Abeera, Furby, Casie, Lerma, James R, Sesterhenn, Thomas M, Pan, Jianmin, Rai, Jayesh, Johnstone, Megan E, Abdul-Aziz, Amina, Johnson, Mariah L, Rai, Shesh N, Byrd, John C, Hertlein, Erin

“…Acute myeloid leukemia (AML) is the malignant proliferation of immature myeloid cells characterized by a block in differentiation. As such, novel therapeutic…”
Get full text

The Potent Dihydroorotate Dehydrogenase Inhibitor, Hosu-53, Exhibits Compelling Monotherapy Efficacy in Multiple Myeloma and Augments CD47 Targeted Therapy by Hilinski, Gerard, Stearns, Blaise, Vibhute, Sandip, Hughes, Tiffany, Tridandapani, Susheela, Johnstone, Megan E., Goodwin, Thomas E., Patrick, Jeffrey, Bennett, Chad E., Benson, Don, Byrd, John C., Elgamal, Ola A., Hertlein, Erin K.

“…Worldwide, multiple myeloma (MM) is the second most common hematological malignancy characterized by the expansion of aberrant mature plasma cells in the bone…”
Get full text

A Novel Selective BCL2 Inhibitor with Limited Immune Suppression and Improved Safety Compared to Venetoclax by Sharpe, Chia, Elgamal, Sara, Fobare, Sydney, Furby, Casie, Long, Marissa, Bryant, Kinsey, Cheney, Carolyn, Lerma, James R., Johnstone, Megan E., Orry, Andrew, Lam, Polo Chun-Hung, Abagyan, Ruben, Kysil, Volodymyr, Gukasyan, Hovhannes, Mitkin, Oleg, Karapetian, Ruben, Ryakhovskiy, Alexey, Bulanova, Elena, Parchinsky, Vladislav, Ivachtchenko, Alexandre, Dokukina, Kate, Pushechnikov, Alexei, Savchuk, Nikolay, Dukes, Iain, Burd, Amy, Hertlein, Erin K., Byrd, John C.

“…BCL2 is a key pro-survival protein that is overexpressed in many cancers. The first generation BCL2 inhibitor venetoclax has proved highly effective in…”
Get full text

Multiomic profiling identifies predictors of survival in African American patients with acute myeloid leukemia by Stiff, Andrew, Fornerod, Maarten, Kain, Bailee N., Nicolet, Deedra, Kelly, Benjamin J., Miller, Katherine E., Mrózek, Krzysztof, Boateng, Isaiah, Bollas, Audrey, Garfinkle, Elizabeth A. R., Momoh, Omolegho, Fasola, Foluke A., Olawumi, Hannah O., Mencia-Trinchant, Nuria, Kloppers, Jean F., van Marle, Anne-Cecilia, Hu, Eileen, Wijeratne, Saranga, Wheeler, Gregory, Walker, Christopher J., Buss, Jill, Heyrosa, Adrienne, Desai, Helee, Laganson, Andrea, Hamp, Ethan, Abu-Shihab, Yazan, Abaza, Hasan, Kronen, Parker, Sen, Sidharth, Johnstone, Megan E., Quinn, Kate, Wronowski, Ben, Hertlein, Erin, Miles, Linde A., Mims, Alice S., Oakes, Christopher C., Blachly, James S., Larkin, Karilyn T., Mundy-Bosse, Bethany, Carroll, Andrew J., Powell, Bayard L., Kolitz, Jonathan E., Stone, Richard M., Duarte, Cassandra, Abbott, Diana, Amaya, Maria L., Jordan, Craig T., Uy, Geoffrey L., Stock, Wendy, Archer, Kellie J., Paskett, Electra D., Guzman, Monica L., Levine, Ross L., Menghrajani, Kamal, Chakravarty, Debyani, Berger, Michael F., Bottomly, Daniel, McWeeney, Shannon K., Tyner, Jeffrey W., Byrd, John C., Salomonis, Nathan, Grimes, H. Leighton, Mardis, Elaine R., Eisfeld, Ann-Kathrin

“…Genomic profiles and prognostic biomarkers in patients with acute myeloid leukemia (AML) from ancestry-diverse populations are underexplored. We analyzed the…”
Get full text

Therapeutic Targeting of FLT3 Gate Keeper Mutation with E2082-0047 in Traditional and a Novel Immunocompetent Murine Adoptive Transfer Model of AML by Elgamal, Ola A., Zapata, Juan Carlos, Li, Haishan, Sharpe, Chia, Fobare, Sydney, Stearns, Blaise, Lerma, James R., Bryant, Kinsey, Furby, Casie, Long, Marissa, Fyock, Kaytlynn, Johnstone, Megan E., Sesterhenn, Thomas M., Wronowski, Benjamin, Pan, Jianmin, Rai, Shesh N., Orry, Andrew, Lam, Polo Chun-Hung, Abagyan, Ruben, Pushechnikov, Alexei, Savchuk, Nikolay, Kysil, Volodymyr, Gukasyan, Hovhannes, Dukes, Iain, Dokukina, Kate, Mitkin, Oleg, Karapetian, Ruben, Ryakhovskiy, Alexey, Bulanova, Elena, Parchinsky, Vladislav, Ivachtchenko, Alexandre, Starczynowski, Daniel T., Burd, Amy, Pauza, C. David, Hertlein, Erin K., Byrd, John C.

“…Signaling mutations such as Fms-like tyrosine kinase 3 (FLT3) internal tandem duplication (FLT3-ITD) occur in approximately 30% of AML patients which provide…”
Get full text

Effects of leucine on mitochondrial biogenesis and cell cycle in A‐375 melanoma cells by Filhiol, Tia M, Johnstone, Megan E, Zemel, Michael B

“…Abstract only Most cancer cells undergo the Warburg effect, a shift from oxidative to glycolytic metabolism accompanied by suppression of p53. We have…”
Get full text